Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis
AJ Genuino, U Chaikledkaew, DO The… - Expert review of …, 2019 - Taylor & Francis
Objective: Breast cancer remains to be the globally leading female cancer. About 15% to
20% of breast cancers have human epidermal growth factor receptor 2 (HER2)-positive …
20% of breast cancers have human epidermal growth factor receptor 2 (HER2)-positive …
[HTML][HTML] Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life …
Background Metastatic breast cancer (MBC) behaviour differs depending on hormone
receptors (HR) and human epidermal growth factor receptor (HER2) statuses. Methods The …
receptors (HR) and human epidermal growth factor receptor (HER2) statuses. Methods The …
Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy
Objectives This study sought to assess the effects of neurohormonal therapies in preventing
cardiotoxicity in patients receiving chemotherapy. Background Various cardioprotective …
cardiotoxicity in patients receiving chemotherapy. Background Various cardioprotective …
Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy
MM Abu-Khalaf, A Safonov, J Stratton, S Wang… - Breast Cancer Research …, 2019 - Springer
Background There is a lack of consensus to guide which breast cancer patients require left
ventricular function assessment (LVEF) prior to anthracycline therapy; the cost-effectiveness …
ventricular function assessment (LVEF) prior to anthracycline therapy; the cost-effectiveness …
[HTML][HTML] Risk factors associated with trastuzumab-induced cardiotoxicity in patients with human epidermal growth factor receptor 2-positive breast cancer
Context: Although trastuzumab is a highly effective and selective targeted therapy for human
epidermal growth factor receptor 2 (HER2)-positive breast cancer, the drug-induced …
epidermal growth factor receptor 2 (HER2)-positive breast cancer, the drug-induced …
[HTML][HTML] The impact of targeted therapy on intracranial metastatic disease incidence and survival
AW Erickson, S Das - Frontiers in Oncology, 2019 - frontiersin.org
Intracranial metastatic disease (IMD) is a common and severe complication of primary
cancers. Current treatment options for IMD include surgical resection and radiation therapy …
cancers. Current treatment options for IMD include surgical resection and radiation therapy …
[PDF][PDF] Efficacy of treatment with carvedilol in preventing early-stage left ventricular dysfunction in patients with breast cancer candidated to receive trastuzumab using …
M Moshkani Farahani, S Nourian, HR Jalalian… - Iranian Heart …, 2019 - journal.iha.org.ir
Background: Treatment-induced cardiotoxicity is one of the major side effects of
trastuzumabtreatment in patients with breast cancer. Left ventricular (LV) dysfunction is the …
trastuzumabtreatment in patients with breast cancer. Left ventricular (LV) dysfunction is the …
[HTML][HTML] Adjuvant trastuzumab chemotherapy in early breast cancer: meta-analysis of randomised trials and cost-effectiveness analysis
TN Doan, J Barendregt - Swiss Medical Weekly, 2019 - smw.ch
BACKGROUND Trastuzumab has a large financial impact on the average cost of breast
cancer treatment. This study reassessed the cost-effectiveness of listing the drug on the …
cancer treatment. This study reassessed the cost-effectiveness of listing the drug on the …
[PDF][PDF] Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis
A Thakkinstiana - EXPERT REVIEW OF CLINICAL …, 2019 - academia.edu
Objective: Breast cancer remains to be the globally leading female cancer. About 15% to
20% of breast cancers have human epidermal growth factor receptor 2 (HER2)-positive …
20% of breast cancers have human epidermal growth factor receptor 2 (HER2)-positive …
[HTML][HTML] Central nervous system failure in Korean breast cancer patients with HER2-enriched subtype: Korean radiation oncology group 16-15 multicenter …
K Kim, KH Shin, JH Kim, DH Choi, W Park… - Journal of Breast …, 2019 - ncbi.nlm.nih.gov
Purpose The purpose of this study was to evaluate the risk of central nervous system (CNS)
failure in Korean patients with human epidermal growth factor receptor 2 (HER2)-enriched …
failure in Korean patients with human epidermal growth factor receptor 2 (HER2)-enriched …